Item 8.01 Other Events.

On January 6, 2020, Minerva Neurosciences, Inc. (the "Company") issued a press release providing details of the Company's completion of patient screening in a Phase 3 clinical trial of roluperidone. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits




(d)   Exhibits



      Exhibit No.                         Description

      99.1            Press Release of the Company dated January 6, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses